ADC Therapeutics SA Business Summary

ADC Therapeutics SA (ADCT) is a commercial-stage biotechnology leader specializing in the development of highly targeted antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. The company generates revenue primarily through net product sales of ZYNLONTA (loncastuximab tesirine), its FDA-approved CD19-directed ADC for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which achieved preliminary 2025 net revenue of approximately $73 million. Its business segments are concentrated in oncology therapeutics, with a strategic focus on expanding ZYNLONTA into earlier lines of therapy and advancing a pipeline that includes ADCT-602 and a PSMA-targeting ADC. Direct competitors include Gilead Sciences, Pfizer (following its acquisition of Seagen), Jazz Pharmaceuticals, and Nuvation Bio; ADC Therapeutics distinguishes itself as a specialized pioneer in pyrrolobenzodiazepine (PBD)-based payload technology, maintaining a competitive niche as a fully integrated commercial entity despite a smaller market share than diversified pharmaceutical giants. The company was co-founded by Stephen Evans Freke and Dr. Chris Martin, the latter of whom transitioned from CEO to a non-executive Director and Chair of the Science and Technology Committee in 2022. The current leadership team is headed by CEO Ameet Mallik, a former Executive Vice President at Novartis with deep expertise in oncology commercialization. Key executives include Chief Financial Officer Jose Carmona, Chief Medical Officer Mohamed Zaki (formerly of AbbVie and Celgene), Chief Technical Officer David Ege, and Chief Scientific Officer Patrick van Berkel. The company is backed by a robust roster of institutional investors, including Redmile Group, LLC, Point72 Asset Management, and Orbimed Advisors, and is governed by a board chaired by Ron Squarer, former CEO of Array BioPharma.